Abstract
PD-(L)1 inhibitors have a prominent role in the treatment (tx) of NSCLC, with pembro a commonly used agent, but with no direct comparisons between inhibitors to date. This global, randomized, Phase II double-blind study (PERLA; NCT04581824) compared the efficacy and safety of dostar + CT versus pembro + CT in patients (pts) with first-line (1L) metastatic non-squamous NSCLC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
